PharmaNet Development Group Appoints Dr. Wolfgang Renz, Senior Vice President, Clinical Operations

PRINCETON, N.J., July 28 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced today that Dr. Wolfgang Renz has joined the Company as Senior Vice President, Clinical Operations. Dr. Renz will be responsible for PharmaNet's clinical operations in both Western and Central/Eastern Europe, as well as the Regional Monitoring Group in North America. He will be based in the Company's office in Zurich, Switzerland.

"We are extremely pleased to have someone of Dr. Renz's stature join the PharmaNet organization," said Dr. Robert Reekie, Chief Operating Officer and Senior Executive Vice President, Late Stage Development. "Wolfgang's broad experience in drug development combined with his energy and commitment to scientific excellence further enhances our extensive global capabilities in clinical operations."

Before joining PharmaNet, Dr. Renz served as General Manager of JSS Medical Research, President of Samaritan Therapeutics and Adjunct Professor of Surgery at McGill University in Montreal, Canada. He has also held senior positions in clinical research organizations and was Chief Executive Officer of Venn Life Sciences Holdings.

Dr. Renz holds a medical degree from Freiburg University and is board certified in Germany in emergency medicine. He has held medical roles in Hoffman-La Roche AG, Merz GmbH and AXCAN Pharma in Canada.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2300 employees in 33 countries and more than 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  

Contact: Anne-Marie Hess

Phone: (609) 951-6842

E-mail: [email protected]



SOURCE PharmaNet Development Group, Inc.

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

Combining an anti-TREM2 antibody with an immuno-oncology drug that blocks PD-1 led to complete tumor control in a mouse study.